Please provide your email address to receive an email when new articles are posted on . The addition of certolizumab pegol to background medication for nonradiographic axial spondyloarthritis is ...
Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who received abatacept or certolizumab pegol were more likely to achieve ...
Certolizumab is a therapeutic monoclonal antibody, prescribed for Crohn's disease and rheumatoid arthritis. The risk or severity of adverse effects can be increased when Certolizumab pegol is combined ...
Discover comprehensive details about Certolizumab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
- New Cimzia® data, with sites in the US, demonstrate safety and efficacy, increased participation in social activities for adult RA patients ATLANTA, June 16 ...
The US Food and Drug Administration (FDA) has approved the tumor necrosis factor (TNF) inhibitor certolizumab pegol (Cimzia, UCB Pharma) for the treatment of adults with active psoriatic arthritis ...
No clinically meaningful disease worsening among women with well-controlled RA, juvenile arthritis. To better understand the real-world prescribing patterns of certolizumab, researchers collected data ...
the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and the disease has not responded to ...
The efficacy and safety of a new tumor necrosis factor inhibitor, certolizumab pegol, in active rheumatoid arthritis has now been assessed in three phase III, multicenter, randomized, double-blind, ...
June 18, 2007 (Barcelona) — The investigative tumor necrosis factor (TNF) inhibitor certolizumab with the addition of polyethylene glycol (Cimzia) might be a more targeted biologic option for the ...
The appraisal committee reviewed the data available on the clinical and cost effectiveness of certolizumab pegol and secukinumab, having considered evidence on the nature of psoriatic arthritis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results